Task order title: next generation GP130/IL-6/STAT3 inhibitors for the prevention of colitis-associated colorectal cancer
Active Awarded Last action
- Contract number
- 75N91022F00002
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,237,620
Award facts
- Opportunity
-
- TORFP2022E02 Solicitation number
- Contract value 100% obligated
- $1,237,620.00 Current and potential, with all options
- Completion date 98% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $2,220 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,235,400 |
About this award
The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 18, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT), a multiple-award indefinite delivery contract with a $1.24 million ceiling for this order.
PREVENT is the National Cancer Institute's structured preclinical drug development vehicle supporting candidate chemopreventive and immunopreventive regimens across three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. This task order funds next-generation GP130/IL-6/STAT3 inhibitor research for prevention of colitis-associated colorectal cancer. Place of performance is Philadelphia, PA. The order is firm fixed price and runs through November 17, 2026.
Service Contract Inventory reporting shows government-invoiced labor of $112 thousand (FY2022), $447 thousand (FY2023), and $448 thousand (FY2024), representing 0.3, 1.1, and 1.2 FTEs respectively. Derived government-paid hourly rates across these years ranged from $157.59 to $202.62 per hour. In FY2024, the prime performed all 2,501 reported contractor hours without subcontractor engagement.
Quick answers
Who was awarded contract 75N91022F00002?
75N91022F00002 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on May 18, 2022.
How much is contract 75N91022F00002 worth?
The government has obligated $1,237,620 on 75N91022F00002.
Is contract 75N91022F00002 an order under another contract?
Yes. 75N91022F00002 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00002 competed?
The extent of competition for 75N91022F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award